Artelo Biosciences, Inc. (NASDAQ:ARTL) Receives Consensus Rating of “Hold” from Analysts

Shares of Artelo Biosciences, Inc. (NASDAQ:ARTL) have been assigned an average recommendation of “Hold” from the five research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $24.00.

A number of research firms have recently issued reports on ARTL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artelo Biosciences in a report on Tuesday, November 11th. Wall Street Zen downgraded shares of Artelo Biosciences to a “strong sell” rating in a research report on Saturday, August 9th. D. Boral Capital reissued a “hold” rating on shares of Artelo Biosciences in a research report on Monday, September 8th. Finally, D Boral Capital downgraded shares of Artelo Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 8th.

Artelo Biosciences Price Performance

ARTL stock opened at $1.85 on Monday. The stock has a market capitalization of $1.30 million, a P/E ratio of -0.09 and a beta of 1.24. Artelo Biosciences has a fifty-two week low of $1.66 and a fifty-two week high of $28.60. The business has a 50-day moving average of $4.05 and a 200-day moving average of $7.47.

Artelo Biosciences (NASDAQ:ARTL) last announced its earnings results on Wednesday, November 12th. The company reported ($3.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($3.15). Equities analysts expect that Artelo Biosciences will post -2.62 EPS for the current year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.